Redwood City, United States
Allakos Inc, founded in 2012, is a notable player in the biopharmaceutical sector, focusing on developing first-in-class antibody-based therapeutics targeting allergic and inflammatory diseases. Based in the United States, this clinical-stage company aims to revolutionize treatment methodologies within its field.
Positioned within the Biopharma and Biotechnology industries, Allakos Inc stands out for its innovative approach in health care and wellness. The company's public status underscores a solid foundation and growth-oriented mindset, attracting significant financial backing in the field.
On 19 September 2022, Allakos Inc secured a substantial $150.00M in Post-IPO Equity investment. Key investors supporting this round include New Enterprise Associates, Alta Partners, Deep Track Capital, Logos Capital, RTW Investments, TCG Crossover, Braidwell, Frazier Life Sciences, Surveyor Capital, and the Biotechnology Value Fund.
Overall, Allakos Inc's focus on cutting-edge therapeutics and its significant backing position it as a promising candidate for further venture capital attention.
